The Predictive Value of p53, p27Kip1, and α-Catenin for Progression in Superficial Bladder Carcinoma

[1]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[2]  P. Gontero*,et al.  Metastasis markers in bladder cancer: a review of the literature and clinical considerations. , 2004, European urology.

[3]  L. Kiemeney,et al.  Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. , 2004, European urology.

[4]  W. Gage,et al.  Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. , 2003, The American journal of pathology.

[5]  N. Smith,et al.  The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. , 2003, The Journal of urology.

[6]  J. Witjes,et al.  Superficial and metachronous invasive bladder carcinomas are clonally related , 2001, International journal of cancer.

[7]  Y. Ito,et al.  Decreasing of p27Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer , 2001, British Journal of Cancer.

[8]  C. Busch,et al.  Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. , 2001, The Journal of urology.

[9]  W. Schulz,et al.  Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. , 2000, Urology.

[10]  P. Korkolopoulou,et al.  Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. , 2000, Human pathology.

[11]  J. Schalken,et al.  Cadherin switching in human prostate cancer progression. , 2000, Cancer research.

[12]  F. Mostofi,et al.  Revised Classification of Urothelial Neoplasms , 2000 .

[13]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[14]  A. Zlotta,et al.  Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. , 1999, The Journal of urology.

[15]  K. Syrigos,et al.  Role of adhesion molecules in bladder cancer: an important part of the jigsaw. , 1999, Urology.

[16]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[17]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[18]  R. Cote,et al.  Prognostic markers in bladder cancer: a contemporary review of the literature. , 1998, The Journal of urology.

[19]  J. Schalken,et al.  Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. , 1996, Cancer research.

[20]  J. Witjes,et al.  Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[21]  N. Shimizu,et al.  p53 gene mutation in recurrent superficial bladder cancer. , 1995, The Journal of urology.

[22]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[23]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[24]  L. Kiemeney,et al.  Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. , 1993, The Journal of urology.

[25]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[26]  N. Heney,et al.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course. , 1992, The Urologic clinics of North America.

[27]  D. Wynford‐Thomas.  P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[28]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[29]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.